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Abstract

Author Manuscript

Whole brain radiotherapy (WBRT) is associated with memory dysfunction. As part of NRG
Oncology RTOG 0933, a phase II study of WBRT for brain metastases that conformally avoided
the hippocampal stem cell compartment (HA-WBRT), memory was assessed pre- and post-HAWBRT using both traditional and computerized memory tests. We examined whether the
computerized tests yielded similar findings and might serve as possible alternatives for assessment
of memory in multi-institution clinical trials. Adult patients with brain metastases received HAWBRT to 30 Gy in ten fractions and completed Hopkins Verbal Learning Test-Revised (HVLT-R),
CogState International Shopping List Test (ISLT) and One Card Learning Test (OCLT), at
baseline, 2 and 4 months. Tests’ completion rates were 52–53 % at 2 months and 34–42 % at 4
months. All baseline correlations between HVLT-R and CogState tests were significant (p ≤
0.003). At baseline, both CogState tests and one component of HVLT-R differentiated those who
were alive at 6 months and those who had died (p ≤ 0.01). At 4 months, mean relative decline was
7.0 % for HVLT-R Delayed Recall and 18.0 % for ISLT Delayed Recall. OCLT showed an 8.0 %
increase. A reliable change index found no significant changes from baseline to 2 and 4 months for
ISLT Delayed Recall (z = −0.40, p = 0.34; z = −0.68, p = 0.25) or OCLT (z = 0.15, p = 0.56; z =
0.41, p = 0.66). Study findings support the possibility that hippocampal avoidance may be
associated with preservation of memory test performance, and that these computerized tests also
may be useful and valid memory assessments in multi-institution adult brain tumor trials.

Keywords
NRG Oncology RTOG 0933; Neurocognitive; HVLT-R; ISLT; OCLT
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Introduction
Formal measurement of neurocognitive functioning (NCF) is included in a subset of brain
cancer trials to quantify impact of tumors and treatments on cognition, particularly memory.
While there is no shortage of NCF tests, a handful are familiar to many investigators, as they
originated as early as the 1940s and have appeared often in important recent trials. One
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distinct advantage of consistent use of a small number of tests is that doing so promotes
efforts to standardize NCF activity across studies [1].
At the same time, strict adherence to a particular protocol may paradoxically discourage
inclusion of NCF in trials. NCF endpoints are often viewed as burdensome for both patients
and staff [2], yet NCF can be defined and measured in many ways, and while one study may
require detailed examination of cognition to address questions of interest properly, another
might require only selective examination or even use of a single proxy. Another unintended
consequence of limiting trials to a particular subset of tests is that it may deter innovation
within the choice of tests used for measurement. For example, the suitability of some NCF
tests for repeated administration for purposes of detecting change over time may be
questioned [3].

Author Manuscript

When NCF is included in a trial, often it serves as the primary endpoint, and memory,
generally the auditory/verbal domain, is frequently the focus, as it is a major component of
quality of life [4] and susceptible to early and sometimes severe deterioration due to tumors
[5] and their treatments [6]. Paper and pencil tests are most often chosen for memory
assessment in adult cancer patients; although, computerized tests are used often in some
brain conditions where cognition is compromised, such as concussion [7] and Alzheimer’s
disease [8]. Recently, computerized tests have begun to be incorporated into cancer studies
[9, 10], including pediatric populations [11].

Author Manuscript

As part of NRG Oncology RTOG 0933 [12], a phase II study of patients with brain
metastases who underwent whole brain radiotherapy (WBRT) but with conformal avoidance
of the peri-hippocampal stem cell region (HA-WBRT), two computerized tests of memory
were included as secondary endpoints, along with the Hopkins Verbal Learning Test-Revised
(HVLT-R) [13], a traditional test of memory used often in adult cancer trials that measured
the study’s primary endpoint. Of interest was whether the computerized tests yield findings
similar to HVLT-R and whether they might serve as possible alternatives for assessment of
memory, within the context of a multi-institution cooperative group trial.

Materials and methods
Protocol approval was received from the Institutional Review Board at each study site and
informed consent obtained from each patient prior to participation. All sites met technology
and training requirements to ensure ability to perform HA-WBRT and administer NCF tests
properly.

Author Manuscript

Patients and intervention
As detailed in our primary publication [12], 113 patients were accrued (average monthly
accrual was 5.9) from March 31, 2011, to November 1, 2012, with 13 patients excluded due
to lack of protocol treatment or study criteria ineligibility, resulting in 100 analyzable
patients (median age 61, 52 % female). All patients had brain metastases outside a 5 mm
margin around the hippocampus. Patient selection and treatment parameters matched the
criteria used in PCI-P-120-9801 [14], a phase III trial of patients who received WBRT (i.e.,
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no conformal avoidance of the peri-hippocampal stem cell region) for brain metastases and
who served as the pre-specified historical control for this study.
WBRT is associated with memory dysfunction in some patients [15, 16], as well as patientreported quality of life [17]. The historical control identified a mean relative decline of 30 %
from baseline to 4-month follow-up in HVLT-R Delayed Recall. The present study
employed intensity-modulated radiotherapy (IMRT) techniques [18] to allow coverage of the
planning target volume while conformally avoiding the hippocampal neural stem cell niche,
an area implicated in new memory formation [19]. Treatment consisted of HA-WBRT to 30
Gy in 10 fractions.
NCF assessment

Author Manuscript

Memory assessment was conducted at baseline, 2 and 4 months. The 12-month data were
not analyzed due to low completion (8–10 %, with more than 50 % loss due to death).
Because HVLT-R Delayed Recall served as the measure for the primary endpoint, with
statistical comparison to HVLT-R Delayed Recall findings from the historical control, the
usual sequence of HVLT-R components was altered to conform to that study’s method,
which consisted of 3 learning trials, followed immediately by the recognition component, a
delay period of 20 min, and then delayed recall; this altered format has also been used in
other phase III cooperative group research [20, 21].

Author Manuscript

Two computerized tests of memory were also included. The International Shopping List Test
(ISLT) [22, 23] is a computer-administered and scored, 16-item (there are shorter versions)
auditory/verbal list-learning task with psychometric properties including reliability and
validity comparable to traditional list-learning tasks [24], but possibly with less
susceptibility to proactive interference, a potential confound [25]. As with HVLT-R and
other word-list tests, words (unseen by the patient) are read aloud by an examiner and
patients immediately recall, in any order, as many words as possible from the list. For ISLT,
timing of oral presentation of the words is cued by their appearance onscreen, and the
examiner enters responses by clicking the list’s words on the computer’s screen (non-list
words said aloud by the patient are indicated by clicking an “Other Word” button). There are
3 learning trials and one delayed recall trial that follows 20 min later. Because each list is
pseudo-randomly generated from a pool of 128 words, 8 lists are possible without overlap.
Content is drawn from food items common to specific geographic locations and languages.
Instructions are available in multiple languages (including variants). A sample screen view
of the test is shown in Fig. 1a.

Author Manuscript

The One Card Learning Test (OCLT), which demonstrates good psychometric properties
including reliability and validity [26–29], involves a visuoperceptual pattern separation
paradigm [30] within a continuous visual recognition task [31], where standard playing
cards are presented one at a time in the center of the computer’s screen. Pattern separation
appears to be a key function of memory activity within the hippocampus and particularly the
dentate gyrus as demonstrated by fMRI [32, 33]. As each card is presented, the patient must
indicate whether that card has been presented previously in the task by pressing buttons
representing “yes” or “no.” The software can generate essentially unlimited content
sequences. Instructions are available in multiple languages (including variants) and OCLT
J Neurooncol. Author manuscript; available in PMC 2017 January 01.
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requires no verbal response or delay period between portions of the test. This version of
OCLT used 88 items. An illustration of the test is shown in Fig. 1b.
The sequence of administration in this protocol was HVLT-R, ISLT and OCLT (OCLT was
administered during the 20-min period between ISLT Immediate and Delayed Recall) at
baseline and 4 months, to allow for proper comparison to historical control. At 2-months
follow-up, as a check for potential effects resulting from the administration sequence of the
tests, their administration sequence was altered to ISLT, OCLT and HVLT-R. (Sequence of
administration was not analyzed due to limited completion rates at 2 and 4 months.) At each
testing session, there was a break of about 10 min with intervening activity between the two
list-learning tasks to lessen the possibility of interference effects.
Statistical analyses

Author Manuscript

Raw test scores were used for statistical analyses. Patients served as their own controls.
Mean relative decline from baseline for each test was assessed with the following formula:
baseline—follow-up/baseline. ISLT and OCLT were further examined via a Reliable Change
Index (RCI). RCIs may be calculated in a number of ways, but they all are a means of
controlling the sources of error associated with repeated NCF assessments. The method
chosen for this study, which uses the within-subject standard deviation, or mean square error
from a linear regression model as the standard error of measurement, is described in detail
elsewhere [34]. Associations between the 3 tests were evaluated using Spearman correlation
coefficients. Due to the rates of patient deaths throughout the study, cases also were split into
two groups to allow for comparisons between those who were alive at 6 months and those
who had died by 6 months; these were evaluated with the Wilcoxon rank-sum test. Because
the study involved multiple comparisons, which increases the likelihood of Type 1 error,
significance level was set at 0.01, rather than 0.05, for all analyses.
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Results
Completion
Of the 100 eligible patients, 92 and 89, respectively, completed HVLT-R, and ISLT and
OCLT, prior to HA-WBRT. Completion for HVLT-R at 2 months was 53 (53 %) cases
analyzed, with 23 not analyzed and 24 deaths; whereas, at 4 months the numbers were 42
(42 %), 17 and 41, respectively. For the CogState tests, at 2 months there were 52 (52 %)
cases analyzed, with 24 not analyzed and 24 deaths, and at 4 months there were 34 (34 %),
25 and 41. For most tests, the largest number of non-analyzable cases was due to data not
submitted.

Author Manuscript

Relative decline and RCI
At 4 months, the mean relative decline was 7.0 % (95 % confidence interval [CI] −4.7–
18.7 %) for HVLT-R Delayed Recall and 18.0 % (95 % CI 5.5–30.5 %) for ISLT Delayed
Recall. OCLT showed an 8.0 % increase (95 % CI −16.9–0.90 %). A reliable change index
(mean = 0, SD = 1) found no significant change from baseline to 2 months and from
baseline to 4 months for ISLT Delayed Recall (z = −0.40, p = 0.34; z = −0.68, p = 0.25,
respectively) or OCLT (z = 0.15, p = 0.56; z = 0.41, p = 0.66, respectively).
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Spearman correlation coefficients are shown in Table 1. All baseline correlations among the
3 tests were significant (0.31–0.71; p ≤ 0.003). For the follow-up time points, associations
between HVLT-R and ISLT Immediate Recall and Delayed Recall (both involve recall of
newly presented material, as when taking an essay test in school) and HVLT-R Immediate
Recognition and OCLT (both involve recognition of material where newly presented
information must be differentiated from that which was not presented, as when taking a
yes/no choice test in school) were emphasized.

Author Manuscript

At 2 and 4 months, Immediate Recall correlations between HVLT-R and ISLT were
significant (0.73 and 0.80, p ≤ 0.0001), as were correlations between HVLT-R and ISLT
Delayed Recall (0.72 and 0.66, p ≤ 0.0001). A relatively strong association may be expected
between these 2 tests since both involve hearing a list of words and recalling them aloud.
Correlations between HVLT-R Immediate Recognition and OCLT were .45 (2 months, p =
0.001) and .46 (4 months, p = 0.007); a relatively weaker association may be expected
between HVLT-R and OCLT, as the two tests represent different NCF domains (auditory
versus visuoperceptual), impart different stimuli (words versus playing cards) and involve
different formats (yes/no recognition of words versus continuous visual recognition of
standard playing cards).
Alive versus deceased at 6 months

Author Manuscript

Median survival was 6.8 months (95 % CI 4.8–10.9 months). As shown in Table 2, baseline
Wilcoxon rank-sum tests found that 4 of the 6 memory test components differed for those
who were alive at 6 months and those who had died by 6 months. Those alive at 6 months
scored higher at baseline for HVLT-R Immediate Recall (median score of 25 for patients
alive at 6 months versus 20 for patients deceased at 6 months, p = 0.008), ISLT Immediate
Recall (27 vs. 23, p = 0.001) and Delayed Recall (10 vs. 7, p = 0.001), and OCLT (0.95 vs.
0.88, p = 0.001), suggesting that the sample may have varied in degree of illness at baseline.
There was a trend toward significance for HVLT-R Delayed Recall (10 vs. 7, p = 0.022), but
the relationship was not significant for HVLT-R Immediate Recognition (12 vs. 11, p =
0.10). Figure 2a displays HVLT-R and ISLT Immediate Recall scores at baseline, 2 and 4
months; the two groups appeared to diverge over time. Figure 2b displays HVLT-R and ISLT
Delayed Recall scores across these time intervals; the two groups appeared to continue to
differ over time. Figure 3a, b display HVLT-R Immediate Recognition and OCLT scores
across the intervals, respectively.

Discussion
Author Manuscript

The present study supports the primary findings of NRG Oncology RTOG 0933 [12], which
found that HA-WBRT is associated with preservation of performance on a memory test used
often in adult cancer trials. It also provides preliminary evidence that two other memory
tests, CogState computerized International Shopping List Test and One Card learning Test,
may be useful and valid measures of memory in multi-institution adult brain tumor trials.
Results are consistent with evidence from a validation study [35] that found 4 CogState
computerized tests (including OCLT) administered to adult brain tumor patients (primarily
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glioblastoma) compared favorably with a traditional paper and pencil battery that included
HVLT-R, suggesting that those tests may be reliable and valid measures with adult brain
tumor populations. Further study of HA-WBRT is needed to determine whether aspects of
cognition, including memory but also other domains such as executive functions, may
benefit from the techniques.

Author Manuscript

The original HVLT [36] included only Immediate Recall and Immediate Recognition tasks
to avoid a need for a delay period (e.g., 20 min) and minimize total task time. Nevertheless,
delayed recall is a useful means of measuring memory (whereas immediate recall is often
used to assess learning) and a delayed recall component was sometimes added by
researchers, as it was when the test was formally revised and became HVLT-R [13]. In that
revision, the recognition component was moved so that it followed delayed recall, which is
the format used in most memory list tasks. To remain consistent with the format of the prespecified historical control study, this study kept the recognition component between
conclusion of Immediate Recall and beginning of Delayed Recall, which limits
generalizability of these data to studies where HVLT-R Recognition followed Delayed
Recall.

Author Manuscript

Compliance with NCF measurement points can be difficult for patients with brain tumors
and may be less than 50 % in multi-institution studies [37]. In this study, completion rates at
4 months for all tests were below 50 %, an important limitation that complicates our
understanding of the effects of treatment on memory. Compliance may have been especially
challenging because patients were asked to undergo three memory tests at each session. The
computerized tests showed a greater drop in compliance at 4 months than did HVLT-R,
possibly due to their following HVLT-R in administration sequence; patients were asked to
complete all tests at each testing session, but were urged, at minimum, to complete the
HVLT-R since it served as the primary endpoint.

Author Manuscript

Previous research has shown that NCF decline correlates with tumor growth [38], and this
study, as with others [39, 40], found that better memory at baseline was associated with
longer survival. It is unclear why HVLT-R Immediate Recognition and Delayed Recall,
unlike HVLT-R Immediate Recall, failed to maintain a performance differentiation between
those who had died at 6 months and those who remained alive, when the difference was
identified by both ISLT conditions and OCLT. One possibility is that it reflects an artifact of
the study’s ordering of HVLT-R components. However, it is also possible that certain
features of the computerized tests may have offered additional precision. For example,
unlike HVLT-R, ISLT does not group words according to semantic categories, whereby
content may be organized strategically by the patient to improve performance [41, 42].
Further, use of semantic clustering may increase between a first and a second session [43].
Unlike ISLT, HVLT-R content may be particularly susceptible since it includes emotionallyladen categories such as weapons (e.g., “bomb”) and alcoholic beverages (e.g., “bourbon”),
and there is evidence that emotionally-arousing content is more readily semantically
categorized [44]. OCLT uses neutral, universal content and does not present an opportunity
to use strategy to improve performance. Further, it minimizes score range restrictions (word
lists usually contain 12–16 words) by computing the arcsine transformation of the square
root of the proportion of correct responses across a large number of items. Last, memory

J Neurooncol. Author manuscript; available in PMC 2017 January 01.

Caine et al.

Page 8

Author Manuscript

assessment in cancer trials has historically relied on auditory list-learning tasks and OCLT
offers investigators the ability to assess visuoperceptual memory.
Potential advantages of computerized NCF tests
As with this study, since NCF measurement often suffers from data completion failure at
follow-up time points, tests should obtain as much information as possible at each
assessment session. Without adding to burden, software-based tests may automatically
capture multiple scores, including accuracy, various error subtypes and speed (in
milliseconds rather than whole seconds timed by hand), with some serving as potential
covariates.

Author Manuscript

Computerized formats allow a research assistant (psychometricians are not required) to
focus solely on proper test administration and may reduce sources of potential error by
automating data capture and scoring. They also may include useful features such as direct
data upload to real-time databases, nearly unlimited numbers of differing test forms and
elimination of time delay periods (e.g., continuous recognition formats) between portions of
a test such as required for immediate and delayed recall. Further, because statistical
measures for differentiating change from stability need not require access to normative data
sets, NCF tasks can be pre-configured to sample populations’ capabilities by a priori
selection of task length, format or difficulty level. For example, Children’s Oncology Group
[45] is studying use of computerized tests in pediatric populations where level of difficulty
can be scaled from children to adults, offering potential for lifespan harmonization of NCF
data. Perhaps surprising is evidence that even the elderly can enjoy computer-based testing
and that some prefer it to paper and pencil tests [46].

Author Manuscript

Use of technology may promote internationalization of studies and allow for greater choice
as to where data are collected, including remote login for test administration (e.g., a primary
care clinic or even the patient’s home). By removing barriers to innovative trials design,
protocols might include more frequent NCF sessions and detailed charting of performance
curves. Studies have found online administration in patients’ homes to be practical with
post-surgical cardiac [47], multiple sclerosis [48] and concussion patients [49]. Cancer
patients appear to find interacting with technology to be the same or preferable to paper and
pencil formats [35, 50].
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Fig. 1.

a Sample screen from ISLT. b Illustration of presentation of OCLT stimuli
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Fig. 2.

a ISLT and HVLT-R Immediate Recall raw scores. b ISLT and HVLT-R Delayed Recall raw
scores
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Fig. 3.

a HVLT-R Immediate Recognition raw scores. b OCLT raw scores
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Table 1

Author Manuscript

Spearman correlation coefficients, 95 % confidence intervals, and significance values
CogState

HVLT-R

ISLT Immediate Recall

OCLT

ISLT Immediate Recall

OCLT

(n = 89)

(n = 89)

(n = 89)

0.71

0.62

0.38

(0.59, 0.80)

(0.47, 0.73)

(0.19, 0.55)

<.0001

< .0001

0.0002

(n = 88)

(n = 88)

(n = 88)

0.67

0.67

0.42

(0.53, 0.77)

(0.53, 0.77)

(0.23, 0.58)

<.0001

< .0001

< .0001

(n = 89)

(n = 89)

(n = 89)

0.44

0.38

0.31

(0.25, 0.59)

(0.18, 0.54)

(0.11, 0.49)

<.0001

0.0003

0.0030

(n = 48)

(n = 49)

(n = 49)

0.73

0.62

0.76

(0.56, 0.84)

(0.41, 0.77)

(0.61, 0.86)

<.0001

< .0001

< .0001

(n = 48)

(n = 49)

(n = 49)

0.73

0.58

0.72

(0.56, 0.84)

(0.36, 0.74)

(0.54, 0.83)

<.0001

< .0001

< .0001

(n = 47)

(n = 48)

(n = 48)

0.22

0.45

0.25

(−0.07, 0.48)

(0.19, 0.65)

(−0.04, 0.50)

0.1328

0.0012

0.0909

(n = 32)

(n = 32)

(n = 32)

0.80

0.46

0.73

(0.63, 0.90)

(0.13, 0.69)

(0.51, 0.86)

<.0001

0.0087

< .0001

(n = 33)

(n = 33)

(n = 33)

0.59

0.41

0.66

(0.31, 0.78)

(0.07, 0.66)

(0.40, 0.82)

0.0003

0.0187

< .0001

(n = 33)

(n = 33)

(n = 33)

0.14

0.46

0.19

(−0.21, 0.46)

(0.14, 0.69)

(−0.16, 0.50)

4-month correlations
ISLT Immediate Recall

ISLT Delayed Recall

Author Manuscript

Delayed Recall

2-month correlations

ISLT Delayed Recall

Author Manuscript

Immediate Recognition

Baseline correlations

ISLT Delayed Recall

Author Manuscript

Immediate Recall

OCLT

J Neurooncol. Author manuscript; available in PMC 2017 January 01.

Caine et al.

CogState

Page 16

HVLT-R

Author Manuscript

Immediate Recall

Immediate Recognition

Delayed Recall

0.4273

0.0068

0.2804
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Author Manuscript
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Table 2

Author Manuscript

Baseline raw score* distributions and significance values by status at 6 months

ISLT Immediate Recall

Alive at 6 months (n = 49)

Died by 6 months (n = 43)

(n = 47)

(n = 42)

Median

27

23

Min–Max

8–40

0–35

(n = 47)

(n = 42)

Median

10

7

Min–Max

0–16

0–13

ISLT Delayed Recall

OCLT

(n = 47)

(n = 42)

Median

0.9473

0.8826

Min–Max

0.47–1.23

0.41–1.09

(n = 49)

(n = 43)

Median

25

20

Min–Max

10–34

8–35

HVLT Immediate Recall

Author Manuscript

HVLT-Delayed Recall

(n = 49)

(n = 43)

Median

10

7

Min–Max

2–12

0–12

(n = 49)

(n = 43)

Median

12

11

Min–Max

0–12

4–12

HVLT-Immediate Recognition

P value§

0.0012

0.0005

0.0014

0.0078

0.0223

0.0945

§

P value from Wilcoxon rank-sum test

*

Author Manuscript

Higher scores reflect better performance for all tests. Scores for HVLT-R and ISLT are in whole words, with score ranges = 0–36 for HVLT-R
Immediate Recall, 0–12 for HVLT-R Immediate Recognition and HVLT-R Delayed Recall, and 0–48 for ISLT Immediate Recall and 0–16 for ISLT
Delayed Recall. Scores for OCLT are arcsine transformations of the square root of the proportion of correct responses and range from 0 to 1.57
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